Cargando…
The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
BACKGROUND: To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (A...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719125/ https://www.ncbi.nlm.nih.gov/pubmed/36463175 http://dx.doi.org/10.1186/s12933-022-01707-1 |
_version_ | 1784843248710189056 |
---|---|
author | Masrouri, Soroush Moazzeni, Seyyed Saeed Cheraghloo, Neda Azizi, Fereidoun Hadaegh, Farzad |
author_facet | Masrouri, Soroush Moazzeni, Seyyed Saeed Cheraghloo, Neda Azizi, Fereidoun Hadaegh, Farzad |
author_sort | Masrouri, Soroush |
collection | PubMed |
description | BACKGROUND: To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (ATP III), and Joint Interim Statement (JIS) criteria. METHODS: The study population included a total of 5,079 participants (2,785 women) aged ≥ 40 years, free of cardiovascular disease (CVD) at baseline. Participants were followed for incident SCD annually up to 20 March 2018. Multivariable Cox proportional hazards regression models were applied to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MetS and its components for incident SCD. RESULTS: The prevalence of MetS ranged from 27.16% to 50.81%, depending on the criteria used. Over a median of 17.9 years of follow-up, 182 SCD events occurred. The WHO, IDF, and JIS definitions were strong predictors of SCD with multivariable-adjusted HRs (95% CI) of 1.68 (1.20–2.35), 1.51 (1.12–2.03), and 1.47 (1.08–1.98), respectively; these associations significantly attenuated after further adjustment for MetS components. MetS by the ATP III definition was not associated with the risk of SCD after controlling for antihypertensive, glucose-lowering, and lipid-lowering medication use. Among the components of MetS, high blood pressure (WHO definition), high waist circumference (using the national cutoff of ≥ 95 cm), and high glucose component by the JIS/IDF definitions remained independent predictors of SCD with HRs of 1.79 (1.29–2.48), 1.46 (1.07–2.00), and 1.52 (1.12–2.05), respectively. CONCLUSIONS: The constellation of MetS, except for when defined with ATP III definition, is a marker for identifying individuals at higher risk for SCD; however, not independent of its components. Among MetS components, abdominal obesity using the population-specific cutoff point, high glucose component (JIS/IDF definitions), and high blood pressure (WHO definition) were independent predictors of SCD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01707-1. |
format | Online Article Text |
id | pubmed-9719125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97191252022-12-04 The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study Masrouri, Soroush Moazzeni, Seyyed Saeed Cheraghloo, Neda Azizi, Fereidoun Hadaegh, Farzad Cardiovasc Diabetol Research BACKGROUND: To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (ATP III), and Joint Interim Statement (JIS) criteria. METHODS: The study population included a total of 5,079 participants (2,785 women) aged ≥ 40 years, free of cardiovascular disease (CVD) at baseline. Participants were followed for incident SCD annually up to 20 March 2018. Multivariable Cox proportional hazards regression models were applied to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MetS and its components for incident SCD. RESULTS: The prevalence of MetS ranged from 27.16% to 50.81%, depending on the criteria used. Over a median of 17.9 years of follow-up, 182 SCD events occurred. The WHO, IDF, and JIS definitions were strong predictors of SCD with multivariable-adjusted HRs (95% CI) of 1.68 (1.20–2.35), 1.51 (1.12–2.03), and 1.47 (1.08–1.98), respectively; these associations significantly attenuated after further adjustment for MetS components. MetS by the ATP III definition was not associated with the risk of SCD after controlling for antihypertensive, glucose-lowering, and lipid-lowering medication use. Among the components of MetS, high blood pressure (WHO definition), high waist circumference (using the national cutoff of ≥ 95 cm), and high glucose component by the JIS/IDF definitions remained independent predictors of SCD with HRs of 1.79 (1.29–2.48), 1.46 (1.07–2.00), and 1.52 (1.12–2.05), respectively. CONCLUSIONS: The constellation of MetS, except for when defined with ATP III definition, is a marker for identifying individuals at higher risk for SCD; however, not independent of its components. Among MetS components, abdominal obesity using the population-specific cutoff point, high glucose component (JIS/IDF definitions), and high blood pressure (WHO definition) were independent predictors of SCD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01707-1. BioMed Central 2022-12-03 /pmc/articles/PMC9719125/ /pubmed/36463175 http://dx.doi.org/10.1186/s12933-022-01707-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Masrouri, Soroush Moazzeni, Seyyed Saeed Cheraghloo, Neda Azizi, Fereidoun Hadaegh, Farzad The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study |
title | The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study |
title_full | The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study |
title_fullStr | The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study |
title_full_unstemmed | The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study |
title_short | The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study |
title_sort | clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: two decades of follow-up from the tehran lipid and glucose study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719125/ https://www.ncbi.nlm.nih.gov/pubmed/36463175 http://dx.doi.org/10.1186/s12933-022-01707-1 |
work_keys_str_mv | AT masrourisoroush theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT moazzeniseyyedsaeed theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT cheraghlooneda theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT azizifereidoun theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT hadaeghfarzad theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT masrourisoroush clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT moazzeniseyyedsaeed clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT cheraghlooneda clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT azizifereidoun clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy AT hadaeghfarzad clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy |